Revance Therapeutics Inc (RVNC)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RVNC? Forum Prognose

Finanzdaten der Revance Therapeutics Inc-Aktie (RVNC)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	25.59% 51.94	69.80	56.78	58.13	49.33
Operating Expenses	20.19% 98.76	123.75	196.07	123.63	107.36
Interest Income/Expense	2.63% 5.256	5.398	5.093	4.368	4.497
Benefits Costs and Expenses	101.46	-	-	-	-
Costs And Expenses	18.01% 101.46	123.75	196.07	123.63	107.36
Depreciation and Amortization	18.78% 0.545	0.671	1.32	2.135	2.004
Operating Income/Loss	13.21% -46.83	-53.95	-139.29	-65.50	-58.03
Income/Loss From Continuing Operations Before Tax	170.95% -49.52	69.80	56.78	58.13	49.33
Income/Loss From Continuing Operations After Tax	11.08% -49.52	-55.70	-141.18	-67.32	-59.79
Income/Loss From Discontinued Operations, Net Of Tax	-3.627	-	-	-	-
Net Income/Loss	4.57% -53.15	-55.70	-141.18	-67.32	-59.79
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	11,642% 91.92	0.7828	86.61	83.69	81.13
Diluted Average Shares	11,642% 91.92	0.7828	86.61	83.69	81.13
Basic Earnings Per Share	7.94% -0.58	-0.63	-1.63	-0.80	-0.74
Diluted Earnings Per Share	7.94% -0.58	-0.63	-1.63	-0.80	-0.74
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-

GMAB

$22.32

1.11%

INCY

$74.12

0.26%

UTHR

$373.97

3.48%

MRNA

$54.36

0.66%

BGNE

$202.64

1.63%

BNTX

$113.10

0.74%